Seroquel on Glucose Metabolism

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Seroquel (quetiapine)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00214578

D1441C00125

Details and patient eligibility

About

The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent.

Exclusion criteria

• Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT.
• Previous use of atypicals (3 months) or other medications that might influence glucose metabolism
• Contraindications or non-responsiveness for any of the treatments or other safety issues
• Expected non-compliance to treatment and/or study procedures

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)